Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ANALYSIS: Boston bags four approvals in July

This article was originally published in Clinica

Executive Summary

It may be coming up to the summer, but the volume of product approvals doesn’t seem to be slowing. A total of 66 passed Clinica’s news desk in July, up from 59 during the same period last year, and 61 in June.

You may also be interested in...



Medtronic’s Prestige LP Joins LDR’s Mob-C In Two-Level Cervical Disc Competition

The US FDA approved Medtronic's artificial disc based on results of a 397-patient trial showing more favorable outcomes with Prestige LP than anterior cervical discectomy and fusion.

What are the hottest innovations from Israel?

Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.

EuroPCR: St Jude and Philips talk up rival intravascular imaging techs

St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT101812

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel